A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021
- Friday, November 12, 2021, 7:20
- PR Newswire
- Add a comment
AGOURA HILLS, Calif., Nov. 12, 2021 /PRNewswire/ — A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of a first-in-class Tmod™ T cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to…
About the Author
admin has written 21729 stories on this site.